HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival.

AbstractCONTEXT:
Diffuse large B-cell lymphoma (DLBCL) can be assigned to prognostic subgroups, including germinal center B-cell (GCB) and activated B-cell subgroups, by using gene expression profiling and, reportedly, immunohistochemistry for CD10, Bcl-6, and multiple myeloma-1/interferon regulatory factor-4 (MUM1/IRF4).
OBJECTIVE:
To compare 2 commercial MUM1/IRF4 antibody formulations for accuracy in subtyping DLBCL against gene expression profiling, compare subtyping to patient survival, and evaluate the usefulness of GCB and non-GCB subtyping in relapsed and transformed DLBCL.
DESIGN:
Evaluation of 2 commercial MUM1/IRF4 antibodies, ICSTAT/M17 and Mum-1p, by using 40 cases of de novo, relapsed, and transformed DLBCL; and comparison of the results obtained with gene expression profiling and survival.
RESULTS:
Immunohistochemistry predicted the gene expression profiling subtype 71.8% and 69.2% of the time overall with use of the Mum-1p and ICSTAT/M17 antibodies, respectively, and 100% and 91.7% of the time when MUM1/IRF4 expression determined subtype. Gene expression profiling and immunohistochemistry revealed nearly identical 5-year overall survival rates for the GCB vs non-GCB subtypes (68.0% for GCB vs 24.7% for non-GCB with use of gene expression profiling [P = .03] and 70.2% vs 18.4%, respectively, with use of immunohistochemistry [P < .001]). When de novo, transformed, and relapsed cases were analyzed separately, 5-year overall survival rates were also significantly different.
CONCLUSIONS:
Immunohistochemistry can be used to subclassify DLBCL, including a very small series of transformed and relapsed cases, into GCB and non-GCB subtypes and predict survival rates similar to those predicted by use of gene expression profiling. The 2 MUM1/IRF4 antibodies performed similarly.
AuthorsChadwick F Haarer, Robin A Roberts, Yvette M Frutiger, Thomas M Grogan, Lisa M Rimsza
JournalArchives of pathology & laboratory medicine (Arch Pathol Lab Med) Vol. 130 Issue 12 Pg. 1819-24 (Dec 2006) ISSN: 1543-2165 [Electronic] United States
PMID17149956 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)
Chemical References
  • Biomarkers, Tumor
  • Interferon Regulatory Factors
  • interferon regulatory factor-4
Topics
  • B-Lymphocytes (pathology)
  • Biomarkers, Tumor (analysis, classification)
  • Cell Transformation, Neoplastic
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Germinal Center (pathology)
  • Humans
  • Immunophenotyping
  • Interferon Regulatory Factors (analysis)
  • Lymphoma, B-Cell (classification, genetics, mortality)
  • Lymphoma, Large B-Cell, Diffuse (classification, genetics, mortality)
  • Neoplasm Recurrence, Local (mortality, pathology)
  • Reproducibility of Results
  • Survival Rate
  • Tissue Array Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: